Physician profile
Kevin E Sherer
NPI 1922097039
$1,961.80
in general payments reported to CMS, 2019-2025
21 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $150 · 2022: $140 · 2023: $138 · 2024: $691 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438 · Education: $28.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.79 |
| Education | $28.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $507.29 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Actelion Pharmaceuticals US, INC. | $492.38 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Inspire Medical Systems, INC. | $173.13 | 2024-2025 | Inspire |
| United Therapeutics Corporation | $116.00 | 2020-2025 | Remodulin, Tyvaso, Remodulin |
| Allergan, INC. | $93.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.68 | 2019-2025 | Jascayd |
| Insmed, INC. | $75.60 | 2022-2025 | Brinsupri, Arikayce |
| Glaxosmithkline, LLC. | $72.06 | 2019-2024 | Nucala |
| Amgen INC. | $65.40 | 2020-2025 | Tezspire |
| Zoll Respicardia, INC. | $43.84 | 2023 | Remede System |
| Jazz Pharmaceuticals INC. | $36.78 | 2019-2024 | |
| Harmony Biosciences LLC | $29.50 | 2020 | |
| Verona Pharma, INC. | $28.25 | 2025 | Ohtuvayre |
| Novo Nordisk INC | $23.71 | 2024 | Wegovy |
| Fisher & Paykel Healthcare INC | $19.76 | 2024 | Fisher & Paykel Healthcare |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.43 | 2019 | |
| Tandem Diabetes Care, INC. | $18.97 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $18.75 | 2020 | |
| Kestra Medical Technology Services, INC. | $17.48 | 2024 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $12.25 | 2019 | |
| Circassia INC. | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Sherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.